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The yeast Candida albicans is an opportunistic fungal pathogen which induces superficial and systemic
infections in immunocompromised patients. Adherence to host tissue is critical to its ability to colonise
and infect the host. The work presented here describes the synthesis of a small library of aromatic
glycoconjugates (AGCs) and their evaluation as inhibitors of C. albicans adherence to exfoliated buccal
epithelial cells (BECs). We identified a divalent galactoside, ligand 2a, capable of displacing over 50% of
yeast cells already attached to the BECs. Fluorescence imaging indicates that 2a may bind to structural
components of the fungal cell wall.
© 2018 Elsevier Masson SAS. All rights reserved.1. Introduction
The attachment of pathogenic microorganisms to the surface of
the host cells is a prequisite for infection [1,2]. Themechanisms that
mediate pathogen adherence often involve microbial proteins,
known as adhesins, that recognise cell surface biomolecules such as
protein receptors and glycans [3]. The development of compounds
capable of blocking the adherence of pathogens to host cells is an
attractive alternative to traditional antibiotic treatments that rely
solely on killing the infective microorganisms [4,5]. There are
several examples in which the anti-adherence approach has been
exploited successfully to design inhibitors of microbial adherence
[6]. Some of these include glycoclusters capable of preventing lung
infection caused by Pseudomonas aeruginosa [7] and glyco-
conjugates used in the treatment of conditions caused by patho-
genic strains of Escherichia coli, such as Crohn's disease [8] and
urinary tract infections [9,10]. The lectins involved in the adherence
processes in these reports (Lec A and Lec B from P. auroginosa and(K. Kavanagh), trinidad.
served.Fim H from E. coli, respectively) have been extensively studied and
detailed knowledge of their structure and binding specificities is
available. This has greatly facilitated the design of high affinity
glycoconjugates that can effectively compete with host cell surface
ligands [11].
Candida albicans is a dimorphoric yeast that can interconvert
from single cells to hyphal forms, and exists in a commensal state in
the mucosae and gastrointestinal tract [12]. In immunocompro-
mised patients C. albicans induces a range of superficial and sys-
temic infections [13], and is the third leading cause of infections
related to medical devices such as catheters [14]. Adherence of
C. albicans to host cells plays an important role in pathogenesis, as it
allows the establishment of a strong link to host cell surfaces and
provides a focal point for infection by enabling persistence in harsh
environments such as the mouth [15]. Interestingly, this highly
adherent organism is also the most pathogenic Candida species and
the major cause of fungal infections [16], indicating that its highly
infectious rate may be related to its strong adherence capacity. In
addition, C. albicans expresses host regulator binding proteins such
as phosphoglycerate mutase (gpm1) [17] and pH-regulated antigen
1 (pra1) [18] that bind to immune regulators such as Factor H and
FHL-1 to avoid immune detection, demonstrating that through
adherence, C. albicans can block activation of immune system
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The oral cavity, in particular, provides surfaces to which
C. albicans can adhere, such as buccal epithelial cells (BECs).
C. albicans is capable of adhering to host cells through the inter-
action of the yeast cell wall and epithelial cell surfaces [16].
Adherence to abiotic and biotic surfaces is achieved by both non-
specific and specific mechanisms: non-specific interactions
involve cell surface hydrophobicity (CSH) [20]. CSH does not play a
dominant role in the adherence process but has been known to
maintain specific interactions between the yeast and the host [21].
Specific adherence mechanisms occur via the binding of adhesins
to receptors on the host cell surface through lectin-like and protein-
protein interactions [22]. Initial reports indicate that some
C. albicans adhesins recognise and bind to a broad range of cell
surface glycans, which include glycosphingolipids such as lacto-
sylceramide [23] and asialo-GM1,24 and host oligosaccharides
containing fucose [25] (Fuc) and N-acetyl-glucosamine (GlcNAc)
[26].
These findings provide evidence that cell surface glycans are
important receptors for C. albicans and warrant the development of
anti-adherence ligands that can mimic them, thus disrupting
C. albicans - epithelial cell interactions. These compounds could
represent a promising strategy to overcome fungal infections.
However, the lack of structural knowledge of the fungal adhesins
that recognise these carbohydrates hampers a focused design
approach such as those described earlier. In this study, we opted
instead to screen a small library of synthetic glycoconjugates with a
diverse presentation of binding epitopes in order to identify
structural features that can lead to effective inhibition of fungal
adherence. Thus, we herein report the synthesis of aromatic-core
glycoconjugates (AGC) which display some of the glycan residues
reported to mediate C. albicans adherence to epithelial cells and
their subsequent evaluation as inhibitors of the adherence of
C. albicans to BECs.
2. Results and discussion
2.1. Synthesis
There are numerous examples of glycoconjugates built upon
aromatic scaffolds, many of which are intended as ligands for
adhesins [27], carbohydrate-binding proteins [28] or sensors for
the detection of pathogens [29,30]. The popularity of AGCs is partly
due to the versatility in functionality and the substitution patterns
that can be achieved from readily available starting materials. Thus,
we decided to explore 1,3 and 1,3,5 functionalized aromatic de-
rivatives as the starting point in the design of the anti-adherence
AGCs library (Scheme 1, Figures SI.1-3).
It is well known that multivalency can be an important factor
that modulates carbohydrate-protein interactions [31]. Hence,
mono- (compounds 1a-c), di- (compounds 2a-f) and trivalent an-
alogues (compounds 3a-c) were investigated. Carbohydrate moi-
eties present in the epithelial cell surface and reported to bind
C. albicans adhesins were selected to be grafted onto the aromatic
scaffold: these included galactose, fucose, mannose, glucose, N-
acetyl glucosamine and lactose derivatives. Triazolyl-containing
spacer groups of different lengths, generated by means of
Copper-Catalyzed Azide-Alkyne Cycloaddition (CuAAC) reactions,
connected the glycosides to the central aromatic core. This meth-
odology has been found to be extremely useful and reliable for the
efficient synthesis of numerous glycoconjugates [32]. With this
modular approach, we were able to readily assemble a small
collection of glycoconjugates in which (i) the carbohydrate moiety,
(ii) the valency and (iii) the distance between the binding epitopes
were varied. This provided sufficient structural diversity for aninitial screening of the requirements for fungal anti-adherence
activity.
The synthesis of one of the divalent analogues, galactoside 2a,
depicted in Scheme 2, is representative for the synthesis of the
other members of the AGCs library. 5-Aminoisophthalic acid was
reacted with propanoyl chloride. The resulting dicarboxilic acid
was reacted with propargyl amine using freshly prepared 4-(4,6-
Dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium chloride
(DMTMM) to give diamide 6 in 78% yield [33]. The attachment of
the carbohydrate moiety to the aromatic scaffold was effected by
means of the CuAAC reaction: in this example, 2,3,4,6-tetra-O-
acetyl-1-b-azido-galactoside [34] was reacted with compound 6
using copper sulphate and sodium ascorbate as the catalytic sys-
tem. If the cycloaddition was carried out using conventional heat-
ing, the reaction times were long (up to 4 days) and the yields were
moderate. However, we found that if the reaction was carried out
using microwave (MW) irradiation, it proceeded with yields up to
82% for the protected glycoconjugate 7a and with a drastic reduc-
tion in reaction times [35]. The deacetylation of compound 7a was
accomplished under mild basic conditions to give the galactosyl
AGC 2a in 96% yield. Following comparable synthetic schemes (see
Supporting Information, Schemes SI.1-3), the remaining mono-, di-
and trivalent AGCs were readily prepared in moderate to good
yields.
2.2. Biological Evaluation
All of the glycoconjugates (with exception of monovalent
fucosyl derivative, compound 1b) were found to be soluble inwater.
The toxicity of the compounds against C. albicans was firstly eval-
uated. None of the compounds showed significant ability to inhibit
the growth of the yeast cells at the range of concentrations used in
the subsequent adherence assays (see Figure SI.4). This implies that
any reduction of adherence observed is not due to toxic effects. The
ability of the glycoconjugates to inhibit the adherence of C. albicans
was then evaluated in different assays:
2.2.1. Exclusion assay
The initial adherence assay was performed by treating
C. albicans with the glycoconjugates, allowing for an incubation
period and then exposing the treated yeast cells to the exfoliated
BECs. The percentage increase or decrease of the number of
C. albicans cells adhering to BECs compared to the adherence of the
untreated yeast is represented in Table 1.
These results show the impact of the valency effect in the anti-
adherence ability of the AGCs: monovalent compounds, in which
only one carbohydrate moiety is present, are considerably less
active than their di- and trivalent counterparts. In addition, it can
be clearly seen that the galactosyl derivatives (2a, 2c, 3a and 3c)
and theN-acetyl glucosamine derivative 2e aremuchmore efficient
at preventing the yeast adherence than any of the other glyco-
conjugates: in particular, divalent galacoside 2a was identified as
the most active compound of the AGCs library screened, showing a
remarkable 80% decrease in adherence of the yeast to the BECs after
treatment. Interestingly, compound 4, a structural analogue of 2a in
which one of the galactosyl moieties has been replaced by
mannose, is only capable of producing a 24% reduction in yeast
adherence. This highlights the importance of a divalent galactosyl
pattern as a recognition motif. The linker connecting the galactosyl
moieties to the aromatic scaffold appears to also influence the anti-
adherence ability of the glycoconjugates: the more flexible O-ga-
lactosides 1c, 2c, 3c inhibited yeast adherence less effectively than
their respective analogues 1a, 2a, 3a, in which the triazolyl spacer
group is directly attached to the anomeric galactosyl carbon. In
addition, divalent galactoside 5, which features no linkers, was only
Scheme 1. Chemical structures and starting materials used in the synthesis of the anti-adherence AGCs library.
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The divalent galactoside 2a was then evaluated at lower concen-
trations (Fig. 1a). Significantly, the anti-adherence ability of this
compound was maintained at a 100-fold dilution concentration
(0.1mg/mL, 138 mM)).2.2.2. Competitive assay
The best performing compound (divalent galactosides 2a) was
then evaluated in a competition assay, in which its anti-adherence
ability was tested in the presence of both C. albicans and BECs. Co-
incubation with compounds 2a resulted in a reduction in adher-
ence of yeast cells to BECs of 65%, even at the lowest concentration
(Fig. 1b).2.2.3. Displacement assay
A further assay was performed where glycoconjugate 2a
(0.1mg/mL, 138 mM)) was added to a mixture of C. albicans and
BECs, which had been previously incubated together. The ability ofthe compound to reverse the adherence of the yeast to the BECs
was then examined. Two controls were used in this assay: control 1
involved the assessment of the binding of C. albicans to BECs prior
to compound exposure; control 2 involved BECs and adherent yeast
cells being re-incubated in PBS for 90min prior to a second filtra-
tion step. It was found that 2a imparted a reduction in adherence of
56% (compared to the control 1) and 31% (compared to the control
2) (Fig. 1). These results suggest that divalent galactoside 2a bind
effectively to C. albicans preventing its interaction with BECs
(Fig. 1d).2.3. Fluorescence imaging
A fluorescently labelled analogue of galactosylated AGC 2a,
compound 8 (Fig. 2), was synthesized to investigate possible sites of
interaction of anti-adherence AGCs with C. albicans (Scheme SI-6).
As controls, C. albicans cells with no treatment were imaged under
an Olympus Fluoview 1000 confocal microscope to discard yeast
Scheme 2. Synthesis of galactosyl AGC 2a. Reagents and conditions: i) C2H5COCl, NEt3,
THF, N2, rt, 22 h, 77%; ii) DMTMM, propargyl amine, DMF, N2, 16 h, 78%; iii) 2,3,4,6-
tetra-O-acetyl-1-b-azido-galactoside, CuSO4.5H2O/Na Asc, CH3COCH3/H2O, 100 C in
MW, 10min, 84%; iv) methanol, NEt3, H2O, 45 C, 6 h, 94%.
Table 1
Effect of AGCs on adherence of C. albicans to BECs (estimated according to exclusion
assays, at AGCs concentration¼ 10mg/mL. SE in all cases was less than 10% of mean
change in adherence).
AGCs % Increase/Decrease of Adherence
1a D- Gal - 14.5
1b L- Fuc - 2
1c D- Gal-b-OC2H4 7.5
2a D-Gal 80
2b L-Fuc 8
2c D-Gal-b-OC2H4 35
2d D-Man þ3
2e D-GlcNAc 45
2f D-Lac þ6.5
3a D-Gal 45
3b L-Fuc 30
3c D-Gal-b-OC2H4 42
4 D-Gal/D-Man 24
5 D-Gal 26
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bated with fluorescein isothiocyanate (FITC, Fig. 2b). Fluorescein
derivative galactoside 8was then co-incubatedwith C. albicans cells
and the cells were imaged (Fig. 2c). In this case, strong localized
fluorescence can be clearly observed. From these images, it can be
deduced that compound 8 is interacting with the surface of the
yeast cells.
These results indicate that the valency of the AGCs strongly in-
fluences their anti-adherence ability: the monovalent derivatives
1a-c did not show any significant activity while the trivalent de-
rivatives 3a-c were moderate inhibitors, with the galactosyl de-
rivatives 3a and 3c achieving as high as 45% and 42% reduction of
adherence of C. albicans to BECs, respectively. Nevertheless, this
study was focused in the divalent AGCs based on a 5-
aminoisophthalic acid scaffold, which may allow for further syn-
thetic versatility.
The results from the anti-adherence assays highlight the po-
tential of divalent galactosyl AGC 2a as an inhibitor of the adher-
ence of C. albicans to BECs. This compound consistently showed the
best anti-adherence activity in the three types of assays performed
(with up to 80% reduction of adherence in the exclusion assays).
Interestingly, divalent compounds analogue in structure to 2a but
featuring carbohydrate moieties other than galactose (compounds
2b, 2d-f) were not as efficient adherence inhibitors as 2a: the
second best performing AGC was the N-acetyl glucosaminederivative 2f (45% reduction of adherence in the exclusion assays).
These results suggest that the divalent presentation of the galactose
epitopes achieved in compound 2a is important in mediating
adherence to C. albicans. Polysaccharides and adhesins present in
C. albicans cell wall mediate many of the adhesion processes of the
yeast [36]. Initial research indicated that the addition of galactose
or galactosamine reduced C. albicans attachment to buccal mucosal
cells in vitro [37]. However, this is in contrast to a study inwhich the
pre-treatment of C. albicans with galactose failed to inhibit adher-
ence [38]. It has also been reported that C. albicans binds specifically
to cell surface glycosphingolipids with terminal galactosyl residues
such as lactosylceramide [Gal-b-(1e4)-Glcb-(1-1)Cer] [23] and
asialo-GM1 [Gal-b-(1e3)-GalNAc-b-(1e4)-Gal-b-(1e4)-Glcb-(1-
1)Cer] by means of fimbrial proteins [24]. This study also reports
that the synthetic disaccharide derivative GalNAc-b-(1e4)-Gal-b-
O(CH2)8CO2CH3 was able to inhibit the binding of C. albicans
fimbriae to BECs in vitro. More recently, a synthetic disaccharide
(Fimbrigal-P) also featuring the terminal GalNAc-b-(1e4)-Gal
motif, was found to reduce fungal burden in an in vivomodel of oral
candidiasis [39]. However, to the best of our knowledge, there are
no Structure-Activity Relationship (SAR) studies of synthetic gly-
coconjugates regarding inhibition of C. albicans adherence that
have identified terminal galactosides as key epitopes mediating
yeast adhesion. A recent study has linked the binding specificities
of some C. albicans adhesins (from the Als family) to human cell
surface glycans based on glycan array screening results: a predicted
glycan determinant for some of these proteins was a di-LacNAc
(Gal-b-1,4-GlcNAc) disaccharide [40]. Further studies are
currently going on in our laboratory to identify the fungal adhesin
that lead compound 2a may be binding to.
3. Conclusion
In conclusion, this work reports the synthesis of a small library
of AGCs designed to conduct a preliminary SAR study on their
ability to inhibit the adherence of the pathogenic yeast C. albicans to
BECs. The anti-adherence assays allowed for the identification of
divalent galactosyl derivative 2a as an efficient inhibitor of
C. albicans adherence, with 2a being able to displace over 50% of
yeast cells already attached to BECs. The precise three-dimensional
presentation of the galactosyl moieties in 2a appears to be a
requirement for efficient adherence inhibition, which suggest that
AGC 2a is interfering with a specific recognition process part of the
complex C. albicans adherence mechanisms. Fluorescence studies
suggest that a potential target for 2a could be indeed a fungal cell
wall adhesin. The synthetic accessibility and high efficacy shown by
2a in the biological assays make this compound a promising lead
for development of new fungal anti-adherence agents, less prone to
the appearance of resistance mechanisms than conventional
fungicidal treatments.
4. Experimental section
Chemistry. General Methods: All reagents for synthesis were
bought commercially and used without further purification.
Tetrahydrofuran (THF) was freshly distilled over sodium wire and
benzophenone. Dichloromethane (DCM) was freshly distilled over
CaH2 prior to use. Reactions were monitored with thin layer
chromatography (TLC) on Merck Silica Gel F254 plates. Detection
was effected by UV (l¼ 254 nm) or charring in a mixture of 5%
sulfuric acid-ethanol. NMR spectra were recorded using Bruker
Ascend 500 spectrometer at 293K. All chemical shifts were refer-
enced relative to the relevant deuterated solvent residual peaks.
Assignments of the NMR spectra were deduced using 1H NMR and
13C NMR, along with 2D experiments (COSY, HSQC and HMBC).
Fig. 1. Effect of divalent galactoside 2a on the adherence of C. albicans to BECs. The data displays average yeast adherence per BEC: a) Exclusion assay: C. albicans was preincubated
with 2a (concentrations 10, 1 and 0.1mg/mL); b) Competition assay: C. albicans, BECs and 2a (concentrations 10, 1 and 0.1mg/mL) were co-incubated; c) Displacement assay:
C. albicans and BECs were co-incubated and compound 2a (concentration 0.1mg/mL) was subsequently added; control 1 involved the assessment of the binding of C. albicans to
BECs prior to compound exposure; control 2 involved BECs and adherent yeast cells being re-incubated in PBS for 90min prior to a second filtration step; d) Optical microscopy
image of C. albicans attached to BEC before (right) after (left) treatment with 2a.
Fig. 2. Confocal microscope images of C. albicans cells: a) without treatment; b) co-incubated with FITC; c) co-incubated with fluorescently labelled galactosyl AGC 8; d) chemical
structure of galactoside 8. A wavelength of 488 nm laser was used for excitation and emission was detected at 500e600 nm.
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performed with Merck Silica Gel 60. Microwave reactions were
carried out using a CEM Discover Microwave Synthesizer. Optical
rotations were obtained from an AA-100 polarimeter and ½aD
values are given in 101 cm [2]$g1. High performance liquid
chromatography analysis (HPLC, Waters Alliance 2695) was per-
formed in final compounds and indicated purity of 95% based on
integrations without the use of an internal standard. Highresolution mass spectrometry (HRMS) was performed on an
Agilent-LC 1200 Series coupled to a 6210 Agilent Time-Of-Flight
(TOF) mass spectrometer equipped with an electrospray source
in both positive and negative (ESIþ/) modes. Infrared spectra
were obtained as a film on NaCl plates or as KBr disks in the region
4000e400 cm1 on a Perkin Elmer Spectrum 100 FT-IR spectro-
photometer. Synthetic schemes and spectroscopic data for all
members of the ACG library are provided in the SI.
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reaction procedures
4.1.1. Method A
Copper sulphate pentahydrate (20mg) and sodium ascorbate
(40mg) were added to a solution of the acetylated sugar azide (1,25
equiv per propargyl group) and the corresponding propargyl amide
scaffold in acetone/water (2:1 ratio). The reaction was allowed to
stir at rt until deemed complete by TLC analysis (typically 16e24 h).
The solvent was removed in vacuo. The residue was dissolved in
DCM, washed with water (x3) and dried (MgSO4). The mixture was
filtered and the solvent was removed in vacuo to yield the crude
product, which was purified by silica gel column chromatography
(DCM:MeOH 98:2e93:7) to give the corresponding product.
4.1.2. Method B
Copper sulphate pentahydrate (20mg) and sodium ascorbate
(40mg) were added to a solution of the acetylated sugar azide (1,25
equiv per propargyl group) and the corresponding propargyl amide
scaffold in acetonitrile/water (2:1 ratio). The reaction was allowed
to stir in the MW at 100 C until deemed complete by TLC analysis
(typically 5e15min). The solvent was removed in vacuo. The res-
idue was dissolved in DCM, washed with water (x3) and dried
(MgSO4). The mixture was filtered and the solvent was removed in
vacuo to yield the crude product, which was purified by silica gel
column chromatography (DCM:MeOH 98:2e93:7) to give the cor-
responding product.
4.1.3. General acetyl ester hydrolysis procedure
The acetylated glycoconjugate was dissolved in methanol/water
(2:1 ratio). NEt3 (0.1mL) was added and the reaction mixture was
allowed to stir at 45 C until completion (typically 6e18 h). The
solution was cooled to rt, Amberlite Hþ was added and the mixture
was allowed to stir for 30min. The solution was filtered and the
solvent was removed in the rotatory evaporator and the residue
was dried under high vacuum or lyophilized to give the deprotected
glycoconjugate.
4.1.3.1. N,N0-di(prop-2-yn-1-yl)-5-propionamidoisophthalamide (6).
5-aminoisophathalic acid (5 g, 27.6mmol) was dissolved in anhy-
drous THF (60mL) under N2 and propionyl chloride (2.7mL,
30.4mmol) was added dropwise. The mixture was allowed to stir
for 5min and NEt3 (5mL, 35.8mmol) was added slowly. The re-
action was left to stir for 22 h. The solvent was removed under
reduced pressure, and the residue was dissolved in hot methanol.
The insoluble material was filtered off and the filtrate was evapo-
rated in a rotatory evaporator to give 5-propionoamidoisophthalic
acid [33], which was used without further purification. (5.03 g,
77%). 5-propionoamidoisophthalic acid (0.78 g, 3.27mmol) and
DMTMM (1.99 g, 7.20mmol) were suspended in anhydrous DMF
(25mL) under N2. After 10min, propargylamine (0.46mL,
7.2mmol) was added and the reaction mixture went clear. It was
left to stir at rt for 16 h. The reaction mixture was poured into ice/
water (30mL) and the precipitated formed was then filtered and
dried on the air to give 6: white amorphous solid (0.79 g, 78%). 1H
NMR (500MHz, DMSO‑d6): d 10.15 (s, 1H, NHCOC2H5), 8.94 (t,
J¼ 5.3 Hz, 2H, NHCH2CCH), 8.18 (s, 2H, AreH), 7.93 (s, 1H, AreH),
4.11e4.00 (m, 4H, NHCH2CCH), 3.13 (s, 2H, NHCH2CCH), 2.35 (q,
J¼ 7.5 Hz, 2H, CH2CH3), 1.10 (t, J¼ 7.5 Hz, 3H, CH2CH3). 13C NMR
(125MHz, DMSO‑d6): d 172.8 (COC2H5), 166.2 (CONHCH2CCH),
140.0 (AreC), 135.3 (AreC), 121.4 (AreCH), 120.7 (AreCH), 81.6
(CH2CCH), 73.4 (CH2CCH), 29.1 (CH2CH3), 10.0 (CH2CH3). IR (KBr):
3289.16, 3241.00, 3093.06, 2977.14, 2116.87, 1682.50, 1570.58 cm1.
HRMS (ESIþ): m/z calcd for C17H17N3O3 þHþ [MþH]þ 312.1343,
found 312.1361.4.1.3.1. N,N0-di-(2,3,4,6-tetra-O-acetyl-b-D-galactopyranosyl-1,2,3-
triazol-4-ylmethylamide)-N 00-propyl-5-aminobenzene-1,3-
dicarboxamide (7a). Prepared from 6 to 2,3,4,6-tetra-O-acetyl-1-b-
azido-D-galactopyranoside [34], according toMethod B: pale yellow
amorphous solid (608mg, 84%). Rf¼ 0.29 (DCM: methanol
9:1). ½a21D -4.3 (c 0.7, DCM). 1H NMR (500MHz, CDCl3): d 9.09 (s, 1H,
NHCOC2H5), 8.21 (s, 2H, NHCH2-triaz), 7.97e7.95 (overlapping of
2 s, 4H, AreH and triaz-H), 7.78 (s, 1H, AreH), 5.89 (d, J¼ 9.2 Hz, 2H,
H-1), 5.54 (t, J¼ 9.7 Hz, 2H, H-2), 5.49 (d, J¼ 3.2 Hz, 2H, H-4), 5.27
(dd, J¼ 10.3, 3.2 Hz, 2H, H-3), 4.59 (dd, J¼ 15.5, 5.2 Hz, 4H, CH2-
triaz), 4.29 (t, J¼ 6.5 Hz, 2H, H-5), 4.16e4.05 (m, 4H, H-6 and H-6‘),
2.30 (q, J¼ 7.5 Hz, 2H, CH2CH3), 2.14 (s, 3H, OAc), 1.93 (s, 6H, OAc x
2), 1.76 (s, 3H, OAc), 1.06 (t, J¼ 7.5 Hz, 3H, CH2CH3). 13C NMR
(125MHz, CDCl3): d 173.4 (COC2H5), 170.4 (CO of OAc), 170.2 (CO of
OAc), 169.9 (CO of OAc), 169.3 (CO of OAc), 166.9 (CONHCH2-triaz),
145.4 (C-triaz), 139.1, 134.7 (each AreC), 121.7 (CH-triaz), 121.4,
120.9 (each AreCH), 86.0 (C-1), 73.8 (C-5), 70.8 (C-3), 68.1 (C-2),
67.0 (C-4), 61.2 (C-6), 35.3 (CH2-triaz), 30.2 (CH2CH3), 20.6(CH3 of
OAc), 20.6 (CH3 of OAc), 20.5 (CH3 of OAc), 20.2 (CH3 of OAc), 9.4
(CH2CH3). IR (film on NaCl): 3290, 2979, 2940, 2120, 1753, 1655,
1599, 1536 cm1. HRMS (ESIþ): m/z calcd. for C45H56N9O21 þHþ
[MþH]þ 1058.3591, found 1058.3602.
4.1.3.1. N,N0-di-(2,3,4-tri-O-acetyl-b-L-fucopyranosyl-1,2,3-triazol-4-
ylmethylamide)-N00-propyl-5-aminobenzene-1,3-dicarboxamide (7b).
Prepared from 6 to 2,3,4-tri-O-acetyl-1-b-azido-L-fucopyranoside
[41] according to Method B: yellow amorphous solid (93mg, 62%).
Rf¼ 0.44 (DCM:MeOH 9:1). ½a19D þ1.6 (c 0.9, DCM). 1H NMR
(500MHz, CDCl3): d 8.37 (s, 1H, NHCOC2H5), 7.97 (s, 2H, triaz-H),
7.94 (s, 2H, AreH), 7.83 (t, J¼ 5.1 Hz, 2H, CONHCH2-triaz), 7.70 (s,
1H, AreH), 5.84 (d, J¼ 9.2 Hz, 2H, H-1), 5.58e5.51 (m, 2H, H-2), 5.38
(d, J¼ 3.3 Hz, 2H, H-4), 5.27e5.23 (m, 2H, H-3), 4.66 (dd, J¼ 15.3,
5.7 Hz, 4H, CH2-triaz), 4.15 (q, J¼ 6.4 Hz, 2H, H-5), 2.38 (qd, J¼ 7.7,
3.7 Hz, 2H, CH2CH3), 2.22 (s, 6H, OAc), 1.99 (s, 6H, OAc), 1.83 (s, 6H,
OAc), 1.24 (d, J¼ 6.4 Hz, 6H, H-6), 1.17 (t, J¼ 7.5 Hz, 3H, CH2CH3). 13C
NMR (125MHz, CDCl3): d 172.8 (NHCOC2H5), 170.5 (CO of OAc),
169.9 (CO of OAc), 169.4 (CO of OAc), 166.7 (CONHCH2-triaz), 145.5
(C-triaz), 139.1 (AreC), 135.0 (AreC), 121.4 (CH-triaz), 121.2
(AreCH), 120.5 (AreCH), 86.3 (C-1), 72.8 (C-5), 71.3 (C-3), 69.9 (C-
4), 68.2 (C-2), 35.5 (CH2-triaz), 30.4 (CH2CH3), 20.7 (CH3 of OAc),
20.5 (CH3 of OAc), 20.3 (CH3 of OAc), 16.1 (C-6), 9.5 (CH2CH3). IR
(film on NaCl): 3318, 2924,1749,1656,1535 cm1. HRMS (ESIþ):m/z
calcd for C41H51N9O17 þ Hþ [MþH]þ 942.9130, found 942.9142.
4.1.3.1. N,N0-di-[2-O-(2,3,4,6-tetra-O-acetyl-b-D-galactopyranosyl)-
ethyl-1,2,3-triazol-4-ylmethylamide)-N00-propyl-5-aminobenzene-
1,3-dicarboxamide (7c). Prepared from 6 and 2-O-(2,3,4,6-tetra-O-
acetyl-b-D-galactopyranosyl)ethyl azide [42] according to Method
B: yellow amorphous solid (545mg, 82%). Rf¼ 0.38 (DCM:MeOH
9:1). ½a25D -9.1 (c 1.1, DCM). 1H NMR (500MHz, CDCl3): d 9.11 (s, 1H,
NHCOC2H5), 8.14 (s, 2H, CONHCH2-triaz), 7.96 (s, 2H, AreH), 7.64 (d,
J¼ 16.6 Hz, 3H, AreH and triaz-H), 5.30 (d, J¼ 3.2 Hz, 2H, H-4), 5.07
(dd, J¼ 10.3, 8.1 Hz, 2H, H-2), 4.94 (dd, J¼ 10.5, 3.2 Hz, 2H, H-3),
4.66e4.36 (m, 10H, CH2-triaz and CH2CH2O and H-1), 4.15 (dd,
J¼ 13.6, 6.4 Hz, 2H, CHO-Gal), 4.09e4.01 (m, 4H, H-6 and H-6‘), 3.88
(ap t, J¼ 6.4 Hz, 4H, CHO-Gal and H-5), 2.27 (d, J¼ 7.0 Hz, 2H,
CH2CH3), 2.06 (s, 6H, OAc), 1.95 (s, 6H, OAc), 1.89 (d, J¼ 2.1 Hz, 12H,
OAc x2), 1.03 (t, J¼ 7.3 Hz, 3H, CH2CH3). 13C NMR (125MHz, CDCl3):
d 173.2 (NHCOC2H5), 170.4 (CO of OAc), 170.2 (CO of OAc), 170.0 (CO
of OAc), 169.7 (CO of OAc), 166.8 (CONHCH2-triaz), 144.7 (C-triaz),
139.3 (AreC), 134.7 (AreC), 123.6 (CH-triaz), 121.1 (AreCH), 120.2
(AreCH), 100.8 (C-1), 70.7 (C-5), 70.6 (C-3), 68.5 (C-2), 67.5
(CH2CH2O), 66.9 (C-4), 61.1 (C-6), 50.00 (CH2CH2O), 35.5 (CH2-
triaz), 30.2 (CH2CH3), 20.7 (CH3 of OAc), 20.6 (CH3 of OAc), 20.6 (CH3
of OAc), 20.5 (CH3 of OAc), 9.5 (CH2CH3). IR (film on NaCl): 3311,
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calcd for C49H64N9O23 þ Hþ [MþH]þ 1146.4115, found 1146.4208.
4.1.3.1. N,N0-di-(2,3,4,6-tetra-O-acetyl-a-D-mannopyranosyl-1,2,3-
triazol-4-ylmethylamide)-N 00-propyl-5-aminobenzene-1,3-
dicarboxamide (7d). Prepared from 6 to 2,3,4,6-tetra-O-acetyl-1-a-
azido-D-mannopyranoside [43] according to Method B: sticky,
yellow amorphous solid (110mg, 82%). Rf¼ 0.42 (DCM:MeOH 9:1).
½a22D þ3 (c 1, DCM). 1H NMR (500MHz, CDCl3): d 8.93 (s, 1H,
NHCOC2H5), 8.23 (s, 2H, NHCH2-triaz), 7.94 (s, 2H, triaz-H), 7.78 (s,
2H, AreH), 7.55 (s, 1H, AreH), 6.11 (s, 2H, H-1), 5.99 (s, 2H, H-2),
5.90 (d, J¼ 9.8 Hz, 2H, H-3), 5.41 (t, J¼ 9.6 Hz, 2H, H-4), 4.65e4.54
(m, 4H, CH2-triaz), 4.27 (dd, J¼ 12.5, 2.9 Hz, 2H, H-6), 4.05 (dd,
J¼ 12.4, 3 Hz, 2H, H-6‘), 3.97 (dd, J¼ 6.0, 3.5 Hz, 2H, H-5), 2.48e2.33
(m, 4H, CH2CH3), 2.17 (d, J¼ 1.2 Hz, 6H, OAc), 2.06 (d, J¼ 1.6 Hz, 6H,
OAc), 2.02e1.96 (m, 12H, OAc x2), 1.14 (dd, J¼ 9.4, 5.5 Hz, 6H,
CH2CH3). 13C NMR (125MHz, CDCl3): d 173.5 (COC2H5), 170.7 (CO of
OAc), 170.0 (CO of OAc), 169.9 (CO of OAc), 169.7 (CO of OAc), 166.6
(CONHCH2-triaz), 145.6 (C-triaz), 138.9 (AreC), 134.4 (AreC), 123.5
(CH-triaz), 121.4 (AreCH),120.2 (AreCH), 84.2 (C-1), 71.8 (C-5), 69.3
(C-3), 68.3 (C-2), 65.6 (C-4), 61.7 (C-6), 35.1 (CH2-triaz), 30.3
(CH2CH3), 20.8 (CH3 of OAc), 20.7 (CH3 of OAc), 20.7 (CH3 of OAc),
20.6 (CH3 of OAc), 20.4 (CH3 of OAc), 9.5 (CH2CH3). IR (film on NaCl):
3429, 2115, 1748, 1646 cm1. HRMS (ESIþ): m/z calcd for
C45H56N9O21 þ Hþ [MþH]þ 1058.3591, found 1058.3593.
4.1.3.1. N,N0-di-(2-Acetamido-2-deoxy-3,4,6-tri-O-acetyl-b-D-gluco-
pyranosyl-1,2,3-triazol-4-ylmethylamide)-1,2,3-triazol-4-
ylmethylamide)-N00-propyl-5-aminobenzene-1,3-dicarboxamide (7e).
Prepared from 6 and 2-acetamido-2-deoxy-,3,4,6-tri-O-acetyl-1-b-
azido-D-glucopyranoside [44] according to Method B: yellow
amorphous solid (60mg, 42%). Rf¼ 0.36 (DCM:MeOH 9:1). ½a26D -30
(c 0.4, DCM). 1H NMR (500MHz, d5-Pyr): d 10.87 (s, 1H, NH), 9.88 (t,
J¼ 5.6 Hz, 2H, NH), 9.74 (d, J¼ 9.0 Hz, 2H, NH), 8.90 (s, 2H, triaz-H),
8.62 (s, 2H, AreH), 8.57 (s, 1H, AreH), 6.77 (d, J¼ 9.9 Hz, 2H, H-1),
6.06 (t, J¼ 9.6 Hz, 2H, H-3 or 4), 5.61 (t, J¼ 9.7 Hz, 2H, H-2),
5.23e5.14 (m, 2H, H-3 or 4), 4.48 (dd, J¼ 12.3, 5.0 Hz, 2H, H-6), 4.38
(d, J¼ 8.2 Hz, 2H, H-5), 4.32 (d, J¼ 12.3 Hz, 2H, H-6‘), 2.43 (q,
J¼ 7.5 Hz, 2H, CH2CH3), 2.10 (s, 3H, OAc), 2.01 (s, 3H, OAc), 1.89 (s,
3H, OAc), 1.72 (s, 3H, OAc), 1.19 (t, J¼ 7.6 Hz, 3H, CH2CH3). IR (ATR):
3305, 3078, 2924, 2850, 1743, 1667, 1651, 1529 cm1. HRMS (ESIþ):
m/z calcd for C45H57N11O19 þ Hþ [MþH]þ1056.3910, found
1056.3942.
4.1.3.1. N,N0-di-[{4-O-(2,3,4,6-tetra-O-acetyl-b-D-galactopyranosyl)-
2 ,3 ,6- t r i -O-acetyl -b-D-g lucopyranosyl }-1,2 ,3- t r iazo l -4-
ylmethylamide)-N00-propyl-5-aminobenzene-1,3-dicarboxamide (7f).
Prepared from 6 and 4-O-(2,3,4,6-tetra-O-acetyl-b-D-galactopyr-
anosyl)-2,3,6-tri-O-acetyl-1-b-azido-D-glucopyranoside [45] ac-
cording toMethod B: sticky, yellow amorphous solid (102mg, 72%).
Rf¼ 0.62 (DCM:MeOH 9:1). ½a22D 11 (c 1, DCM). 1H NMR (500MHz,
CDCl3): d 8.55 (s, 1H, NHCOC2H5), 7.93e7.84 (m, 6H, NHCH2-triaz,
triaz-H and AreH), 7.68 (s, 1H, AreH), 5.84 (d, J¼ 9.2 Hz, 2H, H-1
Gal), 5.53e5.45 (m, 2H, H-2 Gal), 5.40 (dd, J¼ 11.2, 7.2 Hz, 2H, H-3
Gal), 5.35 (dd, J¼ 7.0, 3.5 Hz, 2H, H-4 Glc), 5.11 (dd, J¼ 10.3, 7.9 Hz,
2H, H-2 Glc), 5.02e4.96 (m, 2H, H-3 Glc), 4.63 (dd, J¼ 6.8, 4.3 Hz,
4H, CH2-triaz), 4.57 (d, J¼ 7.9 Hz, 2H, H-1 Glc), 4.47 (dd, J¼ 11.1,
7.8 Hz, 2H, H-6 Glc), 4.18e4.05 (m, 6H, H-60 Glc and H-6 and H-6’
(Gal)), 4.04e3.99 (m, 2H, H-4 Gal), 3.93 (dd, J¼ 14.4, 8.4 Hz, 4H, H-5
Gal and H-5 Glc), 2.40 (q, J¼ 7.2 Hz, 2H, CH2CH3), 2.19e1.92 (m,
42H, OAc x14), 1.81 (s, 3H), 1.19 (t, J¼ 7.5 Hz, 2H, CH2CH3). 13C NMR
(125MHz, CDCl3): d 173.1 (COC2H5), 170.4 (CO of OAc), 170.1 (CO of
OAc), 170.1 (CO of OAc), 169.6 (CO of OAc), 169.5 (CO of OAc), 169.1
(CO of OAc), 166.6 (CONHCH2-triaz), 145.6 (C-triaz), 138.9 (AreC),
134.7 (AreC), 121.5 (CH-triaz), 121.2 (AreCH), 120.7 (AreCH), 101.1(C-1 Glc), 85.5 (C-1 Gal), 76.0 (C-5 Gal), 75.6 (C-4 Gal), 72.6 (C-3
Gal), 70.9 (C-3 Glc), 70.8 (C-2 Gal), 70.7 (C-5 Glc), 69.1 (C-2 Glc),
66.7 (C-4 Glc), 61.9 (C-6 Glc), 60.8 (C-6 Gal), 35.5 (CH2-triaz), 30.4
(CH2CH3), 20.7 (CH3 of OAc), 20.6 (CH3 of OAc), 20.6 (CH3 of OAc),
20.5 (CH3 of OAc), 20.4 (CH3 of OAc), 20.3, 9.5 (CH2CH3). IR (film on
NaCl): 3293, 2942, 1749, 1656, 1599, 1537 cm1. HRMS (ESIþ): m/z
calcd for C69H88N9O37 þ Hþ [MþH]þ 1634.5281, found 1634.5287.
4 .1.3 .1. N ,N 0-d i - (b -D -ga lac topyranosyl -1,2 ,3 - t r ia zo l -4-
ylmethylamide)-N00-propyl-5-aminobenzene-1,3-dicarboxamide (2a).
White amorphous solid (60mg, 94%). ½a25D þ12.7 (c 0.5, H2O). 1H
NMR (500MHz, D2O): d 8.24 (s, 2H, triaz-H), 7.85 (s, 2H, AreH), 7.79
(s, 1H, AreH), 5.66 (d, J¼ 8.8 Hz, 2H, H-1), 4.64 (s, 4H, CH2-triaz),
4.20 (t, J¼ 9.2 Hz, 2H, H-2), 4.08 (d, J¼ 8.6 Hz, 2H, H-4), 3.97 (s, 2H,
H-5), 3.86 (d, J¼ 9.7 Hz, 2H, H-3), 3.75 (d, J¼ 4.7 Hz, 2H, H-6 and H-
6‘), 2.37 (d, J¼ 7.4 Hz, 2H, CH2CH3), 1.12 (t, J¼ 7.3 Hz, 3H, CH2CH3).
13C NMR (125MHz, D2O): d 176.8 (COC2H5), 169.0 (CONHCH2-triaz),
145.2 (C-triaz), 138.2, 134.6 (AreC), 123.0 (CH-triaz), 122.9, 122.1
(AreCH), 88.1 (C-1), 78.3 (C-5), 72.9 (C-3), 69.8 (C-2), 68.6 (C-4),
60.9 (C-6), 35.1 (CH2-triaz), 29.9 (CH2CH3), 9.2 (CH2CH3). IR (KBr):
3368, 2940, 2121, 1649, 1598, 1546 cm1. HRMS (ESIþ): m/z calcd.
for C29H40N9O13 þHþ [MþH]þ722.2746, found 722.2730.
4.1.3.1. N,N0-di-(b-L-fucopyranosyl-1,2,3-triazol-4-ylmethylamide)-
N00-propyl-5-aminobenzene-1,3-dicarboxamide (2b). Pale yellow
amorphous solid (76mg, 92%). ½a23D þ4.3 (c 0.4, H2O). 1H NMR
(500MHz, D2O): d 8.22 (d, J¼ 4.1 Hz, 2H, triaz-H), 7.88 (d, J¼ 1.5 Hz,
2H, AreH), 7.81 (s, 1H, AreH), 5.65e5.61 (d, J¼ 9.2 Hz, 2H, H-1),
4.65 (s, 4H, CH2-triaz), 4.15 (t, J¼ 9.5 Hz, 2H, H-2), 4.08e4.02 (m, 2H,
H-5), 3.90e3.82 (m, 4H, H-3 and H-4), 2.37 (q, J¼ 7.6 Hz, 2H,
CH2CH3), 1.25e1.22 (m, 6H, C6eH3), 1.12 (t, J¼ 7.6 Hz, 3H, CH2CH3).
13C NMR (125MHz, D2O): d 176.6 (COC2H5), 168.7 (CONHCH2-triaz),
144.8 (C-triaz), 138.2 (AreC), 134.4 (AreC), 123.0 (CH-triaz), 122.7
(AreCH), 121.9 (AreCH), 88.1 (C-1), 74.4 (C-5), 73.1 (C-3), 71.2 (C-4),
69.5 (C-2), 35.0 (CH2-triaz), 29.9 (CH2CH3), 15.5 (C-6), 9.1 (CH2CH3).
IR (ATR): 3261, 2917, 2851, 1646, 1601, 1536 cm1. HRMS (ESIþ):m/z
calcd for C29H39N9O11 þ Hþ [MþH]þ 690.6910, found 690.6923.
4.1.3.1. N,N0-di-[2-O-(b-D-galactopyranosyl)-ethyl-1,2,3-triazol-4-
ylmethylamide)-N00-propyl-5-aminobenzene-1,3-dicarboxamide (2c).
Pale brown amorphous solid (55mg, 91%). ½a20D þ2.9 (c 0.3, H2O).
1H NMR (500MHz, D2O): d 8.10 (s, 2H, triaz-H), 8.00 (d, J¼ 1.5 Hz,
2H, AreH), 7.93 (s, 1H, AreH), 4.73e4.67 (m, 8H, CH2-triaz and
CH2CH2), 4.39e4.27 (m, 4H, H-1 and CHCH2), 4.18e4.10 (m, 2H,
CHCH2), 3.90 (dd, J¼ 3.4, 0.8 Hz, 2H, H-4), 3.77e3.68 (m, 4H, H-6
and H-6‘), 3.68e3.61 (m, 2H, H-5), 3.59 (dd, J¼ 9.9, 3.4 Hz, 2H, H-3),
3.48 (dd, J¼ 10.0, 7.8 Hz, 2H, H-2), 2.47 (q, J¼ 7.6 Hz, 2H, CH2CH3),
1.20 (td, J¼ 7.6, 1.6 Hz, 3H, CH2CH3). 13C NMR (125MHz, D2O):
d 176.8 (COC2H5), 168.8 (CONHCH2-triaz), 144.3 (C-triaz), 138.1
(AreC), 134.6 (AreC), 124.8 (CH-triaz), 123.0 (AreCH), 122.1
(AreCH), 103.0 (C-1), 75.1 (C-5), 72.6 (C-3), 70.6 (C-2), 68.5 (C-4),
60.9 (C-6), 35.0 (CH2-triaz), 29.9 (CH2CH3), 9.2 (CH2CH3). IR (KBr):
3365, 3323, 3117, 3053, 2977, 2942, 2882, 1691, 1651, 1614,
1564 cm1. HRMS (ESIþ): m/z calcd for C33H48N9O15 þ Hþ [MþH]þ
810.3270, found 810.3322.
4 .1. 3 .1. N ,N 0-d i - (a - D -mannopyranosy l -1, 2 , 3 - t r i a zo l -4 -
ylmethylamide)-N00-propyl-5-aminobenzene-1,3-dicarboxamide (2d).
Pale yellow amorphous solid (42mg, 88%). ½a22D þ19.1 (c 0.4, H2O).
1H NMR (500MHz, D2O): d 8.14 (s, 2H, triaz-H), 7.85 (s, 2H, AreH),
7.78 (s, 1H, AreH), 6.08 (s, 2H, H-1), 4.75 (s, 2H, H-2), 4.64 (s, 4H,
CH2-triaz), 4.14 (dd, J¼ 9.0, 3.2 Hz, 2H, H-3), 3.86e3.74 (m, 6H, H-4
and H-6 and H-6‘), 3.38e3.29 (m, 2H, H-5), 2.37 (q, J¼ 7.6 Hz, 2H,
CH2CH3), 1.12 (t, J¼ 7.6 Hz, 3H, CH2CH3). 13C NMR (125MHz, D2O):
d 176.4 (COC2H5), 168.5 (CONHCH2-triaz), 145.0 (C-triaz), 138.2
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(AreCH), 86.7 (C-1), 76.2 (C-5), 70.6 (C-3), 68.3 (C-2), 66.6 (C-4),
60.5 (C-6), 35.0 (CH2-triaz), 29.9 (CH2CH3), 9.1 (CH2CH3). IR (KBr):
3375, 2941, 1649, 1555 cm1. HRMS (ESIþ): m/z calcd for
C29H40N9O13 þ Hþ [MþH]þ 722.2746, found 722.2740.
4.1.3.1. N,N0-di-(2-Acetamido-2-deoxy-b-D-glucopyranosyl-1,2,3-
triazol-4-ylmethylamide)-1,2,3-triazol-4-ylmethylamide)-N00-propyl-
5-aminobenzene-1,3-dicarboxamide (2e). Pale yellow amorphous
solid (34mg, 75%). ½a22D -5.2 (c 0.3, H2O). 1H NMR (500MHz, D2O):
d 8.20 (s, 2H, triaz-H), 8.01 (t, J¼ 3.9 Hz, 2H, AreH), 7.96e7.89 (m,
1H, AreH), 5.86 (d, J¼ 9.7 Hz, 2H, H-1), 4.72e4.66 (m, 4H, CH2-
triaz), 4.27 (t, J¼ 10.0 Hz, 2H, H-2), 4.01e3.64 (m, 10H, H-3, H-4, H-
5, H-6 and H-6‘), 2.48 (q, J¼ 7.6 Hz, 2H, CH2CH3), 1.79 (s, 3H, NHAc),
1.21 (t, J¼ 7.6 Hz, 3H, CH2CH3). 13C NMR (125MHz, D2O): d 176.8
(COC2H5), 174.1 (CO of NHAc), 168.9 (CONHCH2-triaz), 123.2
(AreCH), 122.8 (CH-triaz), 122.2 (AreCH), 86.4 (C-1), 78.9 (C-5),
73.5 (C-3), 69.3 (C-4), 60.4 (C-6), 55.4 (C-2), 35.0 (CH2-triaz), 30.0
(CH2CH3), 21.6 (CH3 of NHAc), 9.2 (CH2CH3). IR (ATR): 3370, 2943,
1648, 1557 cm1. HRMS (ESIþ): m/z calcd for C33H45N11O13 þ Naþ
[MþNa]þ 826.3096, found 826.3102.
4.1.3.1. N,N0-di-[{4-O-b-D-galactopyranosyl-b-D-glucopyranosyl}-
1,2,3-triazol-4-ylmethylamide)-N00-propyl-5-aminobenzene-1,3-
dicarboxamide (2f). White amorphous (65mg, 90%). ½a17D þ1.5 (c
0.6, H2O). 1H NMR (500MHz, D2O): d 8.16 (s, 2H, triaz-H), 7.91 (s,
2H, AreH), 7.84 (s, 1H, AreH), 5.72 (d, J¼ 9.2 Hz, 2H, H-1 Glc), 4.64
(s, 4H, CH2-triaz), 4.45 (d, J¼ 7.8 Hz, 2H, H-1 Gal), 4.00 (t, J¼ 9.0 Hz,
2H, H-2 Glc), 3.93e3.87 (m, 3H, H-6 Glc and H-4 Gal), 3.85e3.79 (m,
4H, H-3 Glc, H-4 Glc, H-5 Glc and H-60 Glc), 3.78e3.65 (m, 4H, H-6
Gal, H-60 Gal and H-5 Gal), 3.65e3.57 (m, 2H, H-3 Gal), 3.56e3.49
(m, 2H, H-2 Gal), 2.38 (q, J¼ 7.6 Hz, 1H, CH2CH3), 1.12 (dd, J¼ 9.4,
5.8 Hz, 3H, CH2CH3). 13C NMR (125MHz, D2O): d 168.8 (CONHCH2-
triaz), 145.0 (C-triaz), 138.2 (AreC), 134.4 (AreC), 123.1 (CH-triaz),
122.8 (AreCH), 102.8 (C-1 Gal), 87.2 (C-1 Glc), 77.6 (C-4/5 Glc), 77.2
(C-4/5 Glc), 75.3 (C-5 Gal), 74.4 (C-3 Glc), 72.4 (C-3 Gal), 71.9 (C-2
Glc), 70.9 (C-2 Gal), 68.5 (C-4 Gal), 61.0 (C-6 Gal), 59.7 (C-6 Glc),
35.0 (CH2-triaz), 29.8 (CH2CH3), 9.1 (CH2CH3). IR (KBr): 3412, 2923,
2125, 1644, 1548 cm1. HRMS (ESIþ): m/z calcd for
C41H60N9O23 þ Hþ [MþH]þ 1046.3802, found 1046.2788.
4.1.3.1. N-(prop-2-yn-1-yl)-3-propionamidobenzamide (9).
3-aminobenzoic acid (2 g, 14.6mmol) was dissolved in anhydrous
THF (15mL) under N2 and propionyl chloride (3.19mL, 36.5mmol)
was added dropwise. The mixture was allowed to stir for 5min and
NEt3 (6.1mL, 43.8mmol) was added slowly. The reactionwas left to
stir for 16 h. The solvent was removed in vacuo. The crude mixture
was dissolved in ethyl acetate (30mL), washed with 0.5M HCl
(30mL), and dried (MgSO4). The mixture was filtered and the sol-
vent was removed under reduced pressure to yield the product 3-
(propionylamino) benzoic acid as an off-white amorphous (0.637 g,
23%) which was used without further purification. This acid
(0.307 g, 1.59mmol) and TBTU (0.56 g, 1.75mmol) were dissolved
in anhydrous DMF (15mL) under N2. NEt3 (0.3mL, 2.38mmol) was
added, and the reaction mixture was stirred for 10min on ice.
Propargylamine (0.15mL, 2.38mmol) was added, and the reaction
was stirred for 16 h at rt. The solvent was removed in vacuo. The
crude mixture was dissolved in ethyl acetate (30mL), washed with
0.5M HCl (30mL), sat. NaHCO3 (30mL) and brine (30mL), and
dried (MgSO4). The mixture was filtered and the solvent was
removed in the rotatory evaporator to yield product 9: pale yellow
amorphous (0.359 g, 98%). 1H NMR (500MHz, DMSO‑d6): d 9.99 (s,
1H, NHCH2CCH), 8.86 (s, 1H, NHCOC2H5), 8.04 (s, 1H, AreH), 7.77 (d,
J¼ 8.2 Hz, 1H, AreH), 7.48 (d, J¼ 7.7 Hz, 1H, AreH), 7.37 (t,
J¼ 7.9 Hz, 1H, AreH), 4.03 (dd, J¼ 5.5, 2.4 Hz, 2H, CH2CCH), 3.10 (t,J¼ 2.3 Hz, 1H, CH2CCH), 2.32 (q, J¼ 7.5 Hz, 2H, CH2CH3), 1.08 (t,
J¼ 7.5 Hz, 3H, CH2CH3). 13C NMR (125MHz, DMSO‑d6): d 172.6
(COC2H5), 166.4 (CONHCH2-triaz), 139.9 (AreC), 135.0 (AreC), 129.1
(AreCH), 122.3 (AreCH), 121.8 (AreCH), 118.9 (AreCH), 81.8
(CH2CCH), 73.2 (CH2CCH), 30.0 (CH2CH3), 29.0 (CH2CCH), 10.1
(CH2CH3). IR (KBr): 3365, 3321, 3298, 3117, 2977, 2942, 1690, 1652,
1562 cm1. HRMS (ESIþ): m/z calcd for C13H15N2O2 þHþ [MþH]þ
231.1134, found 231.1135.
4.1.3.1. N-(2,3,4,6-tetra-O-acetyl-b-D-galactopyranosyl-1,2,3-triazol-
4-ylmethylamide)-N0-propyl-3-aminobenzene-1-carboxamide (10a).
Prepared from 9 to 2,3,4,6-tetra-O-acetyl-1-b-azido-D-galactopyr-
anoside [34], according to Method A: Off-white amorphous solid
(235mg, 83%). Rf¼ 0.45 (DCM:MeOH 9:1). ½a19D -6.9 (c 0.9, DCM).
1H NMR (500MHz, CDCl3): d 8.62 (s, 1H, NHCOC2H5), 7.95 (s, 1H,
triaz-H), 7.89e7.78 (m, 2H, AreH x2), 7.72 (s, 1H, NHCH2-triaz), 7.48
(d, J¼ 7.4 Hz, 1H, AreH), 7.28 (t, J¼ 7.8 Hz, 1H, AreH), 5.91 (d,
J¼ 9.2 Hz,1H, H-1), 5.56 (m, 2H, H-2 and H-4), 5.34e5.24 (m, 2H, H-
3), 4.68 (dd, J¼ 14.5, 3.5 Hz, 2H, CH2-triaz), 4.31 (t, J¼ 6.1 Hz, 1H, H-
5), 4.15 (dd, J¼ 11.5, 6.8 Hz, 2H, H-6 and H-6‘), 2.39 (q, J¼ 7.4 Hz, 2H,
CH2CH3), 2.18 (s, 3H, OAc), 2.00 (s, 6H, OAc x2), 1.82 (s, 3H, OAc), 1.18
(t, J¼ 7.5 Hz, 3H, CH2CH3). 13C NMR (125MHz, CDCl3): d 173.0
(NHCOC2H5), 170.4 (CO of OAc), 170.1 (CO of OAc), 169.9 (CO of OAc),
169.1 (CO of OAc), 167.5 (CONHCH2-triaz), 145.4 (C-triaz), 138.8
(AreC), 134.5 (AreC), 129.1 (AreCH), 123.1 (AreCH), 122.3 (AreCH),
121.6 (CH-triaz), 118.5 (AreCH), 86.1 (C-1), 73.9 (C-5), 70.8 (C-3),
68.0 (C-2), 66.9 (C-4), 61.2 (C-6), 35.3 (CH2-triaz), 30.4 (CH2CH3),
20.6 (CH3 of OAc), 20.6 (CH3 of OAc), 20.5 (CH3 of OAc), 20.2 (CH3 of
OAc), 9.6 (CH2CH3). IR (film on NaCl): 3311, 2980, 1753, 1652, 1591,
1553 cm1. HRMS (ESIþ): m/z calcd for C27H34N5O11 þHþ [MþH]þ
604.2255, found 604.2262.
4.1.3.1. N-(2,3,4-tri-O-acetyl-b-L-fucopyranosyl-1,2,3-triazol-4-
ylmethylamide)-N0-propyl-3-aminobenzene-1-carboxamide (10b).
Prepared from 9 to 2,3,4-tri-O-acetyl-1-b-azido-L-fucopyranoside
[41] according to Method A: Off-white amorphous solid (90mg,
76%). Rf¼ 0.56 (DCM:MeOH 9:1). ½a20D : þ16.1 (c 1, DCM). 1H NMR
(500MHz, CDCl3): d 8.32 (s, 1H, NHCOC2H5), 7.90 (s, 1H, triaz-H),
7.87 (d, J¼ 8.0 Hz, 1H, AreH), 7.77 (s, 1H, AreH), 7.46 (m, 2H,
AreH and NHCH2-triaz), 7.28 (t, J¼ 8.0 Hz, 1H, AreH), 5.78 (d,
J¼ 9.2 Hz, 1H, H-1), 5.52e5.46 (m, 1H, H-2), 5.35 (d, J¼ 2.9 Hz, 1H,
H-4), 5.24 (dd, J¼ 10.3, 3.4 Hz, 1H, H-3), 4.66 (dd, J¼ 15.2, 5.6 Hz,
2H, CH2-triaz), 4.11 (q, J¼ 6.4 Hz, 1H, H-5), 2.37 (q, J¼ 7.5 Hz, 2H,
CH2CH3), 2.20 (s, 3H, OAc), 1.97 (s, 3H, OAc), 1.81 (s, 3H, OAc),
1.26e1.13 (m, 6H, C6eH3 and CH2CH3). 13C NMR (125MHz, CDCl3):
d 171.8 (COC2H5), 169.5 (CO of OAc), 168.9 (CO of OAc), 168.2 (CO of
OAc), 166.4 (CONHCH2-triaz), 144.3 (CH-triaz), 137.8 (AreC), 133.6
(AreC), 128.2 (AreCH), 122.1 (AreCH), 121.4 (AreCH), 120.4 (CH-
triaz), 117.4 (AreCH), 85.3 (C-1), 71.7 (C-5), 70.2 (C-3), 68.9 (C-4),
67.2 (C-2), 34.4 (CH2-triaz), 29.5 (CH2CH3), 19.7 (CH3 of OAc), 19.5
(CH3 of OAc), 19.3 (CH3 of OAc), 15.0 (C-6), 8.6 (CH2CH3). IR (film on
NaCl): 3308, 3146, 3085, 2985, 2941, 2248, 1750, 1647, 1591,
1553 cm1. HRMS (ESIþ): m/z calcd for C25H32N5O9 þ Hþ [MþH]þ
546.2200, found 546.2197.
4.1.3.1. N-[2-O-(2,3,4,6-tetra-O-acetyl-b-D-galactopyranosyl)-ethyl-
1,2,3-triazol-4-ylmethylamide)-N0-propyl-3-aminobenzene-1-
carboxamide (10c). Prepared from 9 and 2-O-(2,3,4,6-tetra-O-
acetyl-b-D-galactopyranosyl)ethyl azide [42] according to Method
A: Off-white amorphous solid (97mg, 88%). Rf¼ 0.36 (DCM:MeOH
9:1). ½a23D -3.1 (c 1, DCM). 1H NMR (500MHz, CDCl3): d 8.41 (s, 1H,
NHCOC2H5), 7.90 (d, J¼ 8.0 Hz,1H, AreH), 7.80 (s,1H, AreH), 7.63 (s,
1H, triaz-H), 7.56 (t, J¼ 5.1 Hz, 1H, NHCH2-triaz), 7.46 (d, J¼ 7.7 Hz,
1H, AreH), 7.27 (t, J¼ 8Hz, 1H, AreH), 5.34 (dd, J¼ 3.4, 1.0 Hz, 1H,
H-4), 5.11 (dd, J¼ 12.5, 6.2 Hz,1H, H-2), 4.96 (dd, J¼ 10.5, 3.4 Hz,1H,
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4.42 (d, J¼ 7.9, 1H, H-1), 4.18 (dt, J¼ 10.5, 4.1 Hz, 1H, CHO-Gal), 4.08
(dd, J¼ 11.3, 6.6 Hz, 2H, H-6 and H-6‘), 3.95e3.85 (m, 2H, CHO-Gal
and H-5), 2.36 (q, J¼ 7.5 Hz, 2H, CH2CH3), 2.09 (s, 3H, OAc), 1.99 (s,
3H, OAc), 1.93 (s, 3H, OAc), 1.90 (s, 3H, OAc), 1.16 (t, J¼ 7.6 Hz, 3H,
CH2CH3). 13C NMR (125MHz, CDCl3): d 172.8 (COC2H5), 170.4 (CO of
OAc), 170.2 (CO of OAc), 170.0 (CO of OAc), 169.7 (CO of OAc), 167.3
(CONHCH2-triaz), 144.5 (C-triaz), 138.9 (AreC), 134.6 (AreC), 129.1
(AreCH), 123.8 (CH-triaz), 123.0 (AreCH), 122.2 (AreCH), 118.5
(AreCH), 100.9 (C-1), 70.9 (C-5), 70.6 (C-3), 68.6 (C-2), 67.5
(CH2CH2O-Gal), 66.9 (C-4), 61.2 (C-6), 50.1 (CH2CH2O-Gal), 35.5
(CH2-triaz), 30.5 (CH2CH3), 20.6 (CH3 of OAc), 20.6 (CH3 of OAc),
20.6 (CH3 of OAc), 20.5 (CH3 of OAc), 9.6 (CH2CH3). IR (film on NaCl):
3312, 3146, 2980, 2941, 2250, 2111, 1750, 1649, 1591, 1552 cm1.
HRMS (ESIþ): m/z calcd for C29H37N5O12 þ Hþ [MþH]þ 648.2517,
found 648.2581.
4.1.3.1. N-(b-D-galactopyranosyl-1,2,3-triazol-4-ylmethylamide)-N0-
propyl-3-aminobenzene-1-carboxamide (1a). White amorphous
solid (73mg, 92%). ½a19D þ11.6 (c 0.7, H2O). 1H NMR (500MHz, D2O):
d 8.09 (s,1H, triaz-H), 7.55 (t, J¼ 1.8 Hz,1H, AreH), 7.34 (ddd, J¼ 8.0,
2.1, 1.0 Hz, 1H, AreH), 7.32e7.29 (m, 1H, AreH), 7.21 (t, J¼ 7.9 Hz,
1H, AreH), 5.53 (d, J¼ 9.2 Hz, 1H, H-1), 4.48 (s, 2H, CH2-triaz), 4.07
(t, J¼ 9.5 Hz, 1H, H-2), 3.93 (dd, J¼ 3.3, 0.6 Hz, 1H, H-4), 3.83 (td,
J¼ 6.0, 0.8 Hz, 1H, H-5), 3.72 (dd, J¼ 9.8, 3.3 Hz, 1H, H-3), 3.62 (d,
J¼ 6.1 Hz, 2H, H-6 and H-6‘), 2.24e2.18 (q, J¼ 7.7 Hz, 2H, CH2CH3),
0.99 (t, J¼ 7.6 Hz, 3H, CH2CH3). 13C NMR (125MHz, D2O): d 176.5
(NHCOC2H5), 169.7 (CONHCH2-triaz), 145.0 (C-triaz), 137.5 (AreC),
133.7 (AreC), 129.4 (AreCH), 124.8 (AreCH), 123.5 (AreCH), 123.1
(CH-triaz), 119.8 (AreCH), 88.2 (C-1), 78.3 (C-5), 72.9 (C-3), 69.8 (C-
2), 68.6 (C-4), 60.9 (C-6), 34.9 (CH2-triaz), 29.8 (CH2CH3), 9.2
(CH2CH3). IR (ATR): 3268, 1643, 1588, 1542 cm1. HRMS (ESIþ):m/z
calcd for C19H26N5O7 þHþ [MþH]þ 436.1882, found 436.1826.
4.1.3.1. N-(b-L-fucopyranosyl-1,2,3-triazol-4-ylmethylamide)-N0-pro-
pyl-3-aminobenzene-1-carboxamide (1b). Yellow amorphous solid
(63mg, 94%). ½a23D -6.3 (c 0.6, H2O). 1H NMR (500MHz, DMSO‑d6):
d 10.02 (s, 1H, NHCOC2H5), 9.01 (t, J¼ 5.6 Hz, 1H, NHCH2-triaz), 8.07
(m, 2H, triaz-H and AreH), 7.82 (d, J¼ 8.2 Hz, 1H, AreH), 7.56 (d,
J¼ 7.7 Hz, 1H, AreH), 7.40 (t, J¼ 7.9 Hz, 1H, AreH), 5.47 (d,
J¼ 9.2 Hz, 1H, H-1), 5.20 (d, J¼ 5.9 Hz, 1H, OH), 4.96 (d, J¼ 5.4 Hz,
1H, OH), 4.67 (d, J¼ 5.7 Hz, 1H, OH), 4.61e4.49 (m, 2H, CH2-triaz),
3.99 (dd, J¼ 15.0, 9.1 Hz, 1H, H-2), 3.89 (q, J¼ 6.4 Hz, 1H, H-5), 3.56
(m, 2H, H-3 and H-4), 2.36 (q, J¼ 7.6 Hz, 2H, CH2CH3), 1.16 (d,
J¼ 6.4 Hz, 3H, C6eH3), 1.12 (t, J¼ 7.5 Hz, 3H, CH2CH3). 13C NMR
(125MHz, DMSO‑d6): d 172.6 (COC2H5), 166.7 (CONHCH2-triaz),
145.6 (C-triaz), 139.9 (AreC), 135.3 (AreC), 129.1 (AreCH), 122.3
(AreCH), 122.0 (AreCH), 122.0 (CH-triaz), 119.0 (AreCH), 88.5 (C-1),
74.4 (C-3), 73.7 (C-5), 71.6 (C-4), 69.5 (C-2), 35.4 (CH2-triaz), 30.0
(CH2CH3), 16.9 (C-6), 10.1 (CH2CH3). IR (KBr): 3401, 2925, 1645,
1589, 1542 cm1. HRMS (ESIþ): m/z calcd for C19H25N7O7 þ Hþ
[MþH]þ 436.1832, found 436.1849.
4.1.3.1. N-[2-O-(b-D-galactopyranosyl)-ethyl-1,2,3-triazol-4-
ylmethylamide)-N0-propyl-3-aminobenzene-1-carboxamide (1c).
Off-white amorphous solid (104mg, 87%). ½a24D þ3.8 (c 1, MeOH).
1H NMR (500MHz, D2O): d 8.00 (s, 1H, triaz-H), 7.75 (s, 1H, AreH),
7.56e7.53 (m, 2H, AreH), 7.40 (t, J¼ 7.8 Hz, 1H, AreH), 4.50e4.46
(m, 4H, CH2-triaz and CH2CH2), 4.29e4.20 (m, 2H, H-1 and CHCH2),
4.15e4.10 (m, 1H, CHCH2), 3.89 (s, 1H, H-4), 3.80e3.40 (m, 5H, H-6,
H-6‘, H-2, H-3 and H-5), 2.33 (s, 2H, CH2CH3), 1.08 (s, 3H, CH2CH3).
13C NMR (125MHz, D2O) d 176.9 (COC2H5), 168.8 (CONHCH2-triaz),
144.4 (C-triaz), 137.3 (AreC), 134.0 (AreC), 130.7 (AreCH), 129.6,
127.8 (AreCH), 126.6 (AreCH), 125.2 (CH-triaz), 123.8, 122.1
(AreCH), 103.0 (C-1), 75.1 (C-5), 72.6 (C-3), 70.6 (C-2), 68.5 (C-4),67.8 (CH2CH2), 60.9 (C-6), 50.8 (CH2CH2), 34.8 (CH2-triaz), 29.8
(CH2CH3), 9.3 (CH2CH3). IR (KBr): 3400, 2934, 2615, 1648, 1590,
1549 cm1. HRMS (ESIþ): m/z calcd for C21H29N5O8 þ Hþ [MþH]þ
480.2094, found 480.2107.
4.1.3.1. N,N0,N00-tri-(2,3,4,-tri-O-acetyl-b-L-fucopyranosyl-1,2,3-
triazol-4-ylmethylamide)-benzene-1,3,5-tricarboxamide (12b).
Prepared from 11 [46] and 2,3,4-tri-O-acetyl-1-b-azido-L-fucopyr-
anoside [41] according to Method A: yellow amorphous solid
(93mg, 72%). ½a20D þ24.7 (c 0.9, DCM). 1H NMR (500MHz, CDCl3):
d 8.22 (s, 3H, AreH), 8.06 (s, 3H, NHCH2-triaz), 8.00 (s, 3H, triaz-H),
5.89 (d, J¼ 9.2 Hz, 3H, H-1), 5.55 (t, J¼ 9.7 Hz, 3H, H-2), 5.36 (d,
J¼ 3.0 Hz, 3H, H-4), 5.25 (dd, J¼ 10.2, 3.3 Hz, 3H, H-3), 4.68 (dd,
J¼ 58.5, 10.9 Hz, 6H, CH2-triaz), 4.17 (q, J¼ 6.2 Hz, 3H, H-5), 2.21 (s,
9H, OAc), 1.98 (s, 9H, OAc), 1.77 (s, 9H, OAc), 1.21 (d, J¼ 6.3 Hz, 9H,
C6eH3). 13C NMR (125MHz, CDCl3): d 169.5 (CO of OAc), 168.9 (CO
of OAc), 168.2 (CO of OAc), 165.1 (CONHCH2-triaz), 144.4 (C-triaz),
127.7 (AreCH), 120.6 (CH-triaz), 85.3 (C-1), 71.7 (C-5), 70.2 (C-3),
68.9 (C-4), 67.2 (C-2), 34.4 (CH2-triaz), 19.7 (CH3 of OAc), 19.6 (CH3
of OAc), 19.3 (CH3 of OAc), 15.0 (C-6). IR (KBr): 3411, 2989, 2942,
2115, 1751, 1659, 1537 cm1. HRMS (ESIþ): m/z calcd for
C52H67N12O20 þ Hþ [MþH]þ 1179.4595, found 1179.4610.
4.1.3.1. N,N0,N00-tri-[2-O-(2,3,4,6-tetra-O-acetyl-b-D-galactopyr-
anosyl)-ethyl-1,2,3-triazol-4-ylmethylamide)-benzene-1,3,5-
tricarboxamide (12c). Prepared from 11 and 2-O-(2,3,4,6-tetra-O-
acetyl-b-D-galactopyranosyl)ethyl azide [42] according to Method
A: Off-white amorphous solid (69mg, 50%). ½a23D -5.8 (c 0.7, DCM).
1H NMR (500MHz, CDCl3): d 8.22 (s, 3H, NHCH2-triaz), 8.16 (s, 3H,
triaz-H), 7.67 (s, 3H, AreH), 5.34 (d, J¼ 3.2 Hz, 3H, H-4), 5.12 (dd,
J¼ 10.4, 8.0 Hz, 3H, H-2), 4.98 (dd, J¼ 10.5, 3.4 Hz, 3H, H-3),
4.79e4.50 (m, 12H, CH2-triaz and CH2CH2O), 4.47 (d, J¼ 7.9 Hz, 3H,
H-1), 4.28e4.18 (m, 3H, CHO-Gal), 4.09 (dd, J¼ 11.3, 6.6 Hz, 6H, H-6
and H-6’), 4.00e3.86 (m, 6H, CHO-Gal and H-5), 2.11 (s, 9H, OAc),
2.00 (s, 9H, OAc), 1.93 (s, 18H, OAc x 2). 13C NMR (125MHz, CDCl3):
d 170.4 (CO of OAc), 170.1 (CO of OAc),170.0 (CO of OAc),169.7 (CO of
OAc), 165.9 (CONHCH2-triaz), 144.7 (C-triaz), 134.6 (AreC), 128.5
(CH-triaz), 123.6 (AreCH), 100.9 (C-1), 70.6 (C-5), 68.6 (C-3), 67.5
(C-2), 67.0 (CH2CH2O-Gal), 61.2 (C-4), 50.1 (C-6), 35.5 (CH2-triaz),
20.7 (CH3 of OAc), 20.6 (CH3 of OAc), 20.6 (CH3 of OAc), 20.5 (CH3 of
OAc). IR (film on NaCl): 3391, 2939, 1748, 1661, 1537 cm1. HRMS
(ESIþ):m/z calcd for C66H84N12O33 þ Hþ [MþH]þ 1573.5342, found
1574.5422.
4.1.3.1. N, N 0, N 00-tri-(b-D-galactopyranosyl-1,2,3-triazol-4-
ylmethylamide)-benzene-1,3,5-tricarboxamide (3a). Prepared from
N,N0,N00-tri-(2,3,4,6-tetra-O-acetyl-b-D-galactopyranosyl-1,2,3-
triazol-4-ylmethylamide)-benzene-1,3,5-tricarboxamide (12a)
[47]. Yellow amorphous solid (63mg, 89%). ½a23D þ11.1 (c 0.6, H2O).
1H NMR (500MHz, D2O): d 8.24 (s, 3H, triaz-H), 8.19 (s, 3H, AreH),
5.65 (d, J¼ 9.2 Hz, 3H, H-1), 4.64 (s, 6H, CH2-triaz), 4.19 (t, J¼ 9.5 Hz,
3H, H-2), 4.06 (d, J¼ 3.2 Hz, 3H, H-4), 3.96 (t, J¼ 6.1 Hz, 3H, H-5),
3.85 (dd, J¼ 9.8, 3.3 Hz, 3H, H-3), 3.74 (d, J¼ 6.0 Hz, 6H, H-6 and H-
6’). 13C NMR (125MHz, D2O): d 168.1 (CONHCH2-triaz), 144.8 (C-
triaz),134.3 (AreC), 129.2 (AreCH),123.2 (CH-triaz), 88.2 (C-1), 78.3
(C-5), 73.0 (C-3), 69.8 (C-2), 68.6 (C-4), 60.9 (C-6), 35.1 (CH2-triaz).
IR (KBr): 3402, 1658, 1539, cm1. HRMS (ESIþ): m/z calcd for
C36H48N12O18 þ Hþ [MþH]þ 937.3288, found 937.3201.
4 .1.3 .1. N ,N 0,N 00- t r i - (b - L - fucopyranosyl -1,2 ,3 - t r iazo l -4 -
ylmethylamide)-benzene-1,3,5-tricarboxamide (3b). Yellow amor-
phous solid (53mg, 88%). ½a21:5D -5.6 (c 0.5, H2O). 1H NMR
(500MHz, D2O): d 8.26 (s, 3H, AreH), 8.25 (s, 3H, triaz-H), 5.66 (d,
J¼ 9.2 Hz, 3H, H-1), 4.70 (s, 6H, CH2-triaz), 4.19 (t, J¼ 9.4 Hz, 3H, H-
2), 4.10e4.06 (m, 3H, H-5), 3.91 (dd, J¼ 3.4, 0.8 Hz, 3H, H-4), 3.88
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(125MHz, D2O): d 168.3 (CONHCH2-triaz), 144.9 (C-triaz), 134.3
(AreC), 129.2 (AreCH), 123.0 (CH-triaz), 88.1 (C-1), 74.4 (C-5), 73.1
(C-3), 71.2 (C-4), 69.5 (C-2), 35.1 (CH2-triaz), 15.6 (C-6). IR (KBr):
3381, 1659, 1536 cm1. HRMS (ESIþ): m/z calcd for
C38H54N12O15 þ Naþ [MþNa]þ 941.3729, found 941.3709.
4.1.3.1. N,N0,N00-tri-[2-O-(b-D-galactopyranosyl)-ethyl-1,2,3-triazol-
4-ylmethylamide)-benzene-1,3,5-tricarboxamide (3c). Pale yellow
amorphous solid (34mg, 83%). ½a20D þ5.9 (c 0.7, H2O). 1H NMR
(500MHz, D2O): d 8.31 (bs, 3H, triaz-H), 8.18 (s, 2H, AreH), 8.12 (s,
1H, AreH), 4.71 (bs, 6H, CH2-triaz), 4.58e4.56 (m, 3H, CHCH2),
4.37e4.26 (m, 6H, H-1 and CHCH2), 4.12 (m, 3H, CHCH2), 3.96e3.90
(m, 3H, CHCH2), 3.87 (d, J¼ 3.3 Hz, 3H, H-4), 3.76e3.68 (m, 6H, H-6
and H-6’), 3.65e3.60 (m, 3H, H-5), 3.59e3.56 (m, 3H, H-3),
3.49e3.42 (m, 3H, H-2). 13C NMR (125MHz, D2O): d 167.8
(CONHCH2-triaz), 143.8 (C-triaz), 134.4 (AreC), 129.3 (CH-triaz),
125.3 (AreCH), 124.9 (AreCH) 103.0 (C-1), 96.5, 75.1 (C-5), 72.8 (H-
3), 72.6, 71.9, 70.6 (C-2), 68.6 (C-4), 67.8 (CH2CH2), 61.0, 60.9 (C-6),
60.0, 53.1, 51.0 (CH2CH2), 34.8 (CH2-triaz). IR (ATR): 3267, 2931,
1655, 1537 cm1. HRMS (ESIþ): m/z calcd for C42H60N12O21 þ Hþ
[MþH]þ 1069.4074, found 1069.4091.
4.1.3.1. N-(2,3,4,6-tetra-O-acetyl-b-D-mannopyranosy)l-1,2,3-
tr iazol-4-ylmethylamide-N 0-prop-2-yn-1-yl-N 00-propyl-5-
aminobenzene-1,3-dicarboxamide (13). 6 (435mg, 1.40mmol) and
2,3,4,6-tetra-O-acetyl-1-a-azido-mannoside [43] (131mg,
0.349mmol) were reacted according to Method B: yellow amor-
phous solid (91mg, 34%). Rf¼ 0.45 (DCM:MeOH 9:1). ½a23D þ12.1 (c
0.9, MeOH). 1H NMR (500MHz, CDCl3): d 9.15 (s, 1H, NHCOC2H5),
8.13 (s, 1H, NHCH2-triaz), 8.07 (s, 1H, AreH), 8.02 (s, 1H, AreH), 7.87
(s, 1H, triaz-H), 7.78 (s, 1H, AreH), 7.68 (s, 1H, NHCH2-triaz), 6.04 (s,
1H, H-1), 5.91e5.84 (m, 2H, H-2 and H-3), 5.40 (t, J¼ 9.5 Hz, 1H, H-
4), 4.73e4.58 (m, 2H, CH2-triaz), 4.27 (dd, J¼ 12.5, 4.7 Hz, 1H, H-6),
4.13 (s, 2H, CH2CCH), 4.03 (d, J¼ 10.6 Hz, 1H, H-6‘), 3.96e3.87 (m,
1H, H-5), 2.36 (q, J¼ 7.4 Hz, 2H, CH2CH3), 2.19 (d, J¼ 7.6 Hz, 1H,
CH2CCH), 2.17 (s, 3H, OAc), 2.05 (s, 3H, OAc), 2.02 (s, 3H, OAc), 2.00
(s, 3H, OAc), 1.11 (t, J¼ 7.5 Hz, 3H, CH2CH3). 13C NMR (125MHz,
CDCl3): d 173.5 (COC2H5), 170.6 (CO of OAc), 170.0 (CO of OAc), 169.7
(CO of OAc), 169.6 (CO of OAc), 166.8 (CONHCH2-triaz), 166.7
(CONHCH2-triaz), 145.4 (C-triaz), 139.3 (AreC), 134.6 (AreC), 123.4
(CH-triaz), 121.4 (AreCH x2), 120.7 (AreCH), 84.0 (C-1), 79.7
(CH2CCH), 71.9 (C-5), 69.3 (C-2/C-3), 68.3 (C-2/C-3), 65.6 (C-4), 61.7
(C-6), 35.3 (CH2-triaz), 30.3 (CH2CCH), 29.7 (CH2CH3), 29.3
(CH2CCH), 20.8 (CH3 of OAc), 20.7 (CH3 of OAc), 20.7 (CH3 of OAc),
20.6 (CH3 of OAc), 9.4 (CH2CH3). IR (film on NaCl): 3289, 3082, 2981,
1751, 1653, 1598, 1535 cm1. HRMS (ESIþ): m/z calcd for
C29H39N9O13 þ Naþ [MþNa]þ 744.2565, found 744.2575.
4.1.3.1. N-(2,3,4,6-tetra-O-acetyl-b-D-galactopyranosyl)-1,2,3-
triazol-4-ylmethylamide-N’-(2,3,4,6-tetra-O-acetyl-a-D-mannopyr-
anosyl)-1,2,3-triazol-4-ylmethylamide- N00-propyl-5-aminobenzene-
1,3-dicarboxamide (14). 13 (77mg, 0.112mmol) and 2,3,4,6-tetra-
O-acetyl-b-D-galactopyranosyl azide [34] (50mg, 0.134mmol) were
reacted according to Method B: yellow amorphous solid (100mg,
84%). Rf¼ 0.48 (DCM:MeOH 9:1). ½a21D þ9.0 (c 1, DCM). 1H NMR
(500MHz, CDCl3): d 8.89 (s, 1H, NH), 8.20 (s, 1H, NH), 8.14 (s, 2H,
triaz-H), 8.02 (m, 3H, AreH x2 and NH), 7.81 (s, 1H, AreH), 6.22 (d,
J¼ 1.8 Hz, 1H, (H-1 Man)), 6.12 (dd, J¼ 3.6, 2.0 Hz, 1H, H-2 (Man)),
6.09e6.02 (m, 2H, H-3 (Man) and H-1 (Gal)), 5.75 (t, J¼ 9.7 Hz, 1H,
H-2 (Gal)), 5.67 (dd, J¼ 3.3, 0.7 Hz, 1H, H-4 (Gal)), 5.55 (dd, J¼ 12.5,
6.8 Hz, 1H, H-2 (Gal)), 5.44e5.39 (m, 1H, H-3 (Gal)), 4.87e4.71 (m,
4H, CH2-triaz x2), 4.47e4.39 (m, 2H, H-6 (Man) and H-5 (Gal)), 4.29
(dd, J¼ 11.5, 6.5 Hz, 2H, H-6 and H-6’ (Gal)), 4.22e4.15 (m, 1H, H-6’
(Man)), 4.09 (ddd, J¼ 9.6, 4.4, 2.5 Hz, 1H, H-5 (Man)), 2.52 (q,J¼ 7.4 Hz, 2H, CH2CH3), 2.32 (d, J¼ 4.0 Hz, 6H, OAc x2), 2.20 (s, 3H,
OAc), 2.16 (s, 3H, OAc), 2.14 (s, 3H, OAc), 2.12 (s, 6H, OAc x2), 1.96 (s,
3H, OAc), 1.28 (t, J¼ 7.5 Hz, 3H, CH2CH3). 13C NMR (125MHz, CDCl3):
d 173.4 (COC2H5), 170.8 (CO of OAc), 170.5 (CO of OAc), 170.3 (CO of
OAc), 170.0 (CO of OAc), 170.0 (CO of OAc), 169.8 (CO of OAc), 169.4
(CO of OAc), 166.9 (CONHCH2-triaz), 166.8 (CONHCH2-triaz), 145.8
(C-triaz), 145.7 (C-triaz), 139.2 (AreC), 134.9 (AreC), 134.8 (AreC),
123.6 (AreCH), 121.6 (CH-triaz), 120.7 (AreCH), 86.3 (C-1 Gal), 84.2
(C-1 Man), 74.1 (C-5 Gal), 72.0 (C-5 Man), 71.0 (C-3 Gal), 69.4 (C-3
Man), 68.5 (C-2 Man), 68.2 (C-2 Gal), 67.1 (C-4 Gal), 65.8 (C-4 Man),
61.9 (C-6 Man), 61.3 (C-6 Gal), 35.6 (CH2-triaz), 35.4 (CH2-triaz),
30.5 (CH2CH3), 20.9 (CH3 of OAc), 20.8 (CH3 of OAc), 20.8 (CH3 of
OAc), 20.8 (CH3 of OAc), 20.7 (CH3 of OAc), 20.4 (CH3 of OAc), 9.6
(CH2CH3). IR (film on NaCl): 3311, 3147, 3082, 2981,1750,1657,1599,
1548 cm1. HRMS (ESIþ): m/z calcd for C45H56N9O21 þ Hþ
[M þ Hþ]: 1058.3591, found 1058.3607.
4.1.3.1. N-b-D-galactopyranosyl-1,2,3-triazol-4-ylmethylamide-N0-a-
D-mannopyranosyl-1,2,3-triazol-4-ylmethylamide)-N00-propyl-5-
aminobenzene-1,3-dicarboxamide (4). Pale yellow amorphous solid
(84mg, 89%). ½a26D þ13.1 (c 0.8, H2O). 1H NMR (500MHz, D2O):
d 8.23 (s, 1H, triaz-H), 8.14 (s, 1H, triaz-H), 7.85 (s, 1H, AreH), 7.83 (s,
1H, AreH), 7.77 (s, 1H, AreH), 6.07 (d, J¼ 2.2 Hz, 1H, H-1 Man), 5.65
(d, J¼ 9.2 Hz, 1H, H-1 Gal), 4.72 (dd, J¼ 6.4, 3.6 Hz, 1H, H-2 Man),
4.62 (s, 4H, CH2-triaz x2), 4.18 (t, J¼ 9.5 Hz, 1H, H-2 Gal), 4.10 (dd,
J¼ 9.0, 3.4 Hz,1H, H-3Man), 4.06 (d, J¼ 3.2 Hz,1H, H-4 Gal), 3.96 (t,
J¼ 6.0 Hz, 1H, H-5 Gal), 3.85 (dd, J¼ 9.8, 3.2 Hz, 1H, H-3 Gal),
3.81e3.70 (m, 5H, H-4 Man, H-6, H-60 Gal, H-6, H-60 Man), 3.30
(ddd, J¼ 8.9, 5.1, 1.7 Hz, 1H, H-5 Man), 2.35 (q, J¼ 7.6 Hz, 2H,
CH2CH3), 1.10 (t, J¼ 7.6 Hz, 3H, CH2CH3). 13C NMR (125MHz, D2O):
d 176.3 (COC2H5), 168.4 (CONHCH2-triaz), 144.7 (C-triaz), 138.2
(AreC), 134.2 (AreC), 123.8 (CH-triaz), 123.1 (CH-triaz), 122.3
(AreCH), 121.7 (AreCH), 88.2 (C-1 Gal), 86.8 (C-1 Man), 78.3 (C-5
Gal), 76.2 (C-2 Man), 72.9 (C-3 Gal), 70.5 (C-3 Man), 69.8 (C-2 Gal),
68.6 (C-4 Gal), 68.3 (C-2 Man), 66.6 (C-4 Man), 60.9 (C-6 Gal), 60.5
(C-6 Man), 35.0 (CH2-triaz), 34.9 (CH2-triaz), 29.8 (CH2CH3), 9.1
(CH2CH3). IR (ATR): 3259, 2922, 2597, 1648, 1600, 1536 cm1. HRMS
(ESIþ): m/z calcd for C29H39N9O13 þ Naþ [MþNa]þ744.2565, found
744.2575.
4.1.3.1. N,N0-di-(2,3,4,6-tetra-O-acetyl-b-D-galactopyranosyl)-N00-
propyl-5-aminobenzene-1,3-dicarboxamide (15).
5-Propionamidoisophthalic acid (0.133 g, 5.61mmol) and TBTU
(0.396 g, 1.23mmol) were dissolved in DMF (10mL) under N2. NEt3
(0.312mL, 2.24mmol) was added and the mixture was allowed to
stir for 15min. 2,3,4,6-tetra-O-acetyl-b-D-galactopyranosylamine
[48] (0.487 g, 1.40mmol) was dissolved in DMF (5mL) and was
added to the reactionmixture. The solutionwas stirred for 24 h. The
crude mixture was dissolved in DCM (30Ml), washed with 0.5M
HCl (30mL), sat. NaHCO3 (30mL) and brine (30mL), and dried
(MgSO4). The mixture was filtered and the solvent was removed in
vacuo to yield the crude product, which was purified by silica gel
column chromatography (EtOAc) to give the pure product. Yellow
amorphous solid (343mg, 68%). Rf¼ 0.64 (DCM:MeOH 9:1) ½a25D
-18.1 (c 1.1, DCM). 1H NMR (500MHz, CDCl3): d 8.41 (s, 1H, NH), 8.23
(s, 2H, AreH), 7.86 (s, 1H, AreH), 7.54 (d, J¼ 9.1 Hz, 2H, NH), 5.59 (t,
J¼ 8.9 Hz, 2H, H-1), 5.47 (d, J¼ 1.5 Hz, 2H, H-4), 5.31e5.29 (m, 4H,
H-2 and H-3), 4.20 (t, J¼ 6.6 Hz, 2H, H-5), 4.16e4.05 (m, 4H, H-6
and H6‘), 2.42 (q, J¼ 7.5 Hz, 2H), 2.17 (s, 6 H CH3 of OAc), 2.01 (s, 6H,
CH3 of OAc), 1.99 (s, 6H, CH3 of OAc), 1.97 (s, 6H, CH3 of OAc). 13C
NMR (125MHz, CDCl3): d 172.8 (COC2H5), 171.3 (CO of OAc), 170.5
(CO of OAc), 170.2 (CO of OAc), 170.1 (CO of OAc), 166.2 (CONH-Gal),
139.7 (AreC), 134.3 (AreC), 121.9 (AreCH), 120.7 (AreCH), 79.0 (C-
1), 72.4 (C-5), 71.1 (C-2/3), 68.6 (C-2/3), 67.4 (C-4), 61.3 (C-6), 30.5
(CH2CH3), 20.8 (CH3 of OAc), 20.7 (CH3 of OAc), 20.7 (CH3 of OAc),
H. Martin et al. / European Journal of Medicinal Chemistry 160 (2018) 82e939220.6 (CH3 of OAc), 9.4 (CH2CH3). IR (film on NaCl): 3338, 1750, 1602,
1535, cm1. HRMS (ESIþ):m/z calcd for C39H50N3O21 þ Hþ [MþH]þ
896.2931, found 896.2956.
4.1.3.1. N, N0-di-(b-D-galactopyranosyl)-N00-propyl-5-aminobenzene-
1,3-dicarboxamide (5). White amorphous solid (26mg, 96%).
½a20D þ10.0 (c 1, MeOH). 1H NMR (500MHz, D2O): d 8.04 (d,
J¼ 1.4 Hz, 2H, AreH), 8.03 (d, J¼ 1.5 Hz, 1H, AreH), 5.10 (d,
J¼ 8.4 Hz, 2H, H-1), 3.97 (d, J¼ 3.0 Hz, 2H, H-4), 3.82 (t, J¼ 6.2 Hz,
2H, H-5), 3.79e3.67 (m, 8H, H-2, H-3, H-6, H-6‘), 2.47e2.37 (m, 2H,
CH2CH3), 1.19e1.11 (m, 3H, CH2CH3). 13C NMR (126MHz, D2O)
d 176.9 (COC2H5), 170.2 (CONH-Gal), 137.6 (AreC), 134.4 (AreC),
124.1 (AreCH),123.0 (AreCH), 80.5 (C-1), 77.0 (C-5), 73.5 (C-3), 69.3
(C-2), 68.7 (C-4), 61.0 (C-6), 29.9 (CH2CH3) 9.2 (CH2CH3). HRMS
(ESIþ): m/z calcd for C23H34N3O13 þ Hþ [MþH]þ 560.2086, found
560.2072.Biology
4.1.4. Sample Preparation
All glycoconjugates (with exception of monovalent fucosyl de-
rivative, compound 1b) were dissolved in water at the required
concentration (10mg/mL) and dilutions from these stock solutions
were performed as appropriate. Compound 1b was dissolved in
DMSO and diluted with water to the required concentration
(10mg/mL), ensuring that the final DMSO content was below 10%.
Dilutions from this stock solution were performed as appropriate.
4.1.5. Fungal Strain
C. albicans was maintained on sabouraud dextrose agar and
cultures were grow to the stationary phase (1e2 108/ml) over-
night in YEPD broth (1% (w/v) yeast extract, 2% (w/v) bacteriological
peptone, 2% (w/v) glucose) at 30 C and 200 rpm. Stationary phase
yeast cells were harvested, washed with PBS and resuspended at a
density of 1 108/mL in PBS.
4.1.5.1Buccal epithelial cells
Buccal epithelial cells (BECs) were harvested from healthy vol-
unteers by gently scraping the inside of the cheek with a sterile
tongue depressor. Cells were washed in PBS and resuspended at a
density of 5 105/ml.
4.1.6. Adherence assays
Yeast cells were mixed with BECs in a ratio of 50:1 in a final
volume of 2mL and incubated at 30 C and 200 rpm for 90min. The
BEC/yeast cell mixture was harvested by passing through a poly-
carbonate membrane containing 30 mm pores which trapped the
BECs but allowed unattached yeast cells to pass through. This was
washed x 2 with 10mL PBS and cells remaining on the membrane
were collected and placed on glass slides which were left to air dry
overnight. The cells were heat fixed and stained using 0.5% (w/v)
crystal violet, rinsed using cold water to remove any surplus stain
and left to air dry for 30min. The number of C. albicans cells
adhering to a sample of 200 BECs per treatment was assessed
microscopically. In the exclusion assay the yeast cells were incu-
bated for 90min in the presence of each compound (10mg/mL).
After this time the cells were harvested and washed twice with PBS
before being resuspended in 1mL PBS before being mixed with
BECs (as described). In the competition assay format yeast cells,
BECs and compound (10, 1 or 0.1mg/mL) were co-incubated for
90min prior to harvesting. In the displacment assay adherence was
allowed to occur by mixing the yeast cells and BECs together. BECs
and adherent yeast cells were harvested and re-incubated with the
compound (0.1mg/mL) for a further 90min after which time the
level of adherence was measured.
4.1.7. Statistics
All experiments were performed on three independentoccasions. In each assay the number of yeast cells adhering to 200
randomly chosen BECs was determined. Results are mean± SEM.
4.2. Fluorescence imaging
An Olympus Fluoview FV1000 confocal microscope was
employed to visualise the binding of the fluorescently labelled
galactoside 8 to the C. albicans cell surface. A wavelength of 488 nm
laser was used for excitation and emission was detected at
500e600 nm.
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